Therapeutic interchange in Minnesota Hospital pharmacies

Hospital Pharmacy

Volumn 31, Issue 6, 1996, Pages 682-688

  O'Connell, Mary Beth ^a   Seay, Russell E ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

therapeutic alternative; therapeutic interchange; therapeutic interchange physician not contacted (TIPNC)

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTACID AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTITUSSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CEPHALOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAXATIVE; LOOP DIURETIC AGENT; MACROLIDE; METHYLXANTHINE; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PENICILLIN DERIVATIVE; POTASSIUM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; THIAZIDE DIURETIC AGENT; VITAMIN;

DRUG COST; HEALTH CARE FACILITY; HEALTH CARE POLICY; HOSPITAL PERSONNEL; HOSPITAL PHARMACY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACIST; PHARMACOECONOMICS; PHYSICIAN; PRESCRIPTION; REVIEW; TEACHING HOSPITAL; TOPICAL DRUG ADMINISTRATION; UNITED STATES;

EID: 0029954229     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. American College of Clinical Pharmacy. ACCP position statement: Guidelines for therapeutic interchange. Pharmacother 1993;13:252-256.
2. American College of Physicians Therapeutic substitution and formulary systems. Ann Intern Med. 1990;113:160-103.
3. American Medical Association. AMA policy on drug formularies and therapeutic interchange in inpatient and ambulatory patient care settings. Am J Hosp Pharm. 1994;51:1808-1810.
4. American Society of Hospital Pharmacists. Technician status, therapeutic interchange are subjects of resolutions by National Association of Boards of Pharmacy. Am J Hosp Pharm. 1993;50:1535-1538.
5. Zellmer WA. The rise of therapeutic interchange. Am J Hosp Pharm. 1994;51:1838.
6. Oh T, Franko TG Comprehensive therapeutic interchange program in a community hospital Am J Hosp Pharm. 1991;48:1471-1477.
7. Martin LA, Watkins JB, Greene SA et al. Procedural compliance and clinical outcome associated with therapeutic interchange of extended-spectrum penicillins. Am J Hosp Pharm. 1990;47:1551-1554.
8. Lawrenz CA, Cole P, Theodorou A et al. Therapeutic interchange of ampicillin-sulbactam for cefoxitin. Am J Hosp Pharm. 1991,48:2150-2154.
9. Brown GR, Clarke AM. Therapeutic interchange of cefazolin with metronidazole for cefoxitin. Am J Hosp Pharm. 1992;49:1946-1950.
10. Martinusen S, Chen D. Frighetto I, et al., Comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program. Can Med Assoc J. 1993;148:1161-1169.
11. Gutensohn A, Bunz D, Frighetto L et al., Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital. Chemotherapy. 1991;37(Suppl 3):15-21.
12. McDonough KP, Weaver RH, Viall GD. Enalapril to lisinopril: Economic impact of a voluntary angiotensin-converting enzyme-inhibitor substitution program in a staff-model health maintenance organization. Ann Pharmacother. 1992;26:399-404.
13. Rich DS. Experience with a two-tiered therapeutic interchange policy. Am J Hosp Pharm. 1989;46:1792-1798.
14. Oh T, Franko TG. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine. Am J Hosp Pharm. 1990;47:1547-1551.
15. Stock AJ, Kofoed L. Therapeutic interchange of fluoxetine and sertraline: Experience in the clinical setting. Am J Hosp Pharm. 1994:51:2279-2281.
16. Santell JP.ASHP national survey of hospital-based pharmaceutical services - 1994. Am J Health-Syst Pharm. 1995;52:1179- 1198.
17. Crawford SY, Santell JP. ASHP national survey of pharmaceutical services in federal hospitals - 1993. Am J Hosp Pharm. 1994;51:2377-2393
18. Doering PL, Russell WL, McCormick WC et al. Therapeutic substitution in the health maintenance organization outpatient environment. Drug Intell Clin Pharm. 1988;22:125-130